Psychoemotional disorders of patients with inflammatory bowel diseases: prevalence, pathogenesis and treatment options

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, according to the World Gastroenterological Organization occupy one of the leading places in the structure of diseases of the gastrointestinal tract of the rate of spread and relevance of research in most countries of the world. The currently existing therapy regimens, which are standardized depending on the form of the disease and the severity of the course, do not take into account the psycho-emotional component of the disease. Progressive course, frequent exacerbations, restriction of social activity, the presence of extra-intestinal manifestations and complications lead to early disability and significantly worsen the quality of life of patients with inflammatory bowel disease.

Full Text

Restricted Access

About the authors

Igor G. Bakulin

North-Western State Medical University named after I.I. Mechnikov

Email: igbakulin@yandex.ru
ORCID iD: 0000-0002-6151-2021
SPIN-code: 5283-2032
Scopus Author ID: 6603812937
ResearcherId: P-4453-2014

MD, Dr. Sci. (Med.), Professor

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015

Venera Sh. Stamboltsyan

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: stamboltsyan95@mail.ru
ORCID iD: 0000-0002-0134-8856
SPIN-code: 4965-6390

MD

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015

Inna A. Oganezova

North-Western State Medical University named after I.I. Mechnikov

Email: oganezova@rambler.ru
ORCID iD: 0000-0003-0844-4469
SPIN-code: 4981-9153

MD, Dr. Sci. (Med.), Professor

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015

References

  1. Inflammatory Bowel Disease [Internet]. World Gastroenterology Organisation. Available from: https://www.worldgastroenterology.org/guidelines/inflammatory-bowel-disease-ibd. Accessed: 25.05.2023.
  2. Klinicheskie rekomendatsii “Yazvennyy kolit” [Internet]. Available from: https://legalacts.ru/doc/klinicheskie-rekomendatsii-iazvennyikolit-utv-minzdravom-rossii. Accessed: 18.09.2021. (In Russ.)
  3. Ivashkin VT, Shelygin YuA, Abdulganieva DI, et al. Crohn’s disease. Clinical recommendations (preliminary version). Koloproktologia. 2020;19(2(72)):8–38. (In Russ.) doi: 10.33878/2073-7556-2020-19-2-8-38
  4. Knyazev OV, Shkurko TV, Fadeyeva NA, et al. Epidemiology of chronic inflammatory bowel disease. Yesterday, today, tomorrow. Experimental and Clinical Gastroenterology. 2017;139(3):4–12. (In Russ.)
  5. Bakulin IG, Skalinskaya MI, Skazyvaeva EV. North-Western register of patients with inflammatory bowel diseases: achievements and lessons learned. Koloproktologia. 2022;21(1):37–49. (In Russ.) doi: 10.33878/2073-7556-2022-21-1-37-49
  6. Bakulin IG, Skalinskaya MI, Maev IG, et al. Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management. Тerapevticheskii Arkhiv. 2021;8(93):841–852. (In Russ.) doi: 10.26442/00403660.2021.08.200982
  7. Keller R, Mazurak N, Fantasia L, et al. Quality of life in inflammatory bowel diseases: it is not all about the bowel. Intest Res. 2021;19(1):45–52. doi: 10.5217/ir.2019.00135
  8. Knowles SR, Graff LA, Wilding H, et al. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-Part I. Inflamm Bowel Dis. 2018;4(24):742–751. doi: 10.1093/ibd/izx100
  9. Maev IV, Shelygin YuA, Skalinskaya MI, et al. Pathomorphosis of inflammatory bowel diseases. Annals of the Russian Academy of Medical Sciences. 2020;75(1):27–35. (In Russ.) doi: 10.15690/vramn1219
  10. Ozer M, Bengi G, Colak R, et al. Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life. Medicine (Baltimore). 2020;99(19):e20067. doi: 10.1097/MD.0000000000020067
  11. Alexander F. Psychosomatic medicine. Principles and application. Transl. by A.M. Bokovikov, V.V. Starovoitov. Ed. by S.L. Shishkin. Moscow; 2006. (In Russ.)
  12. James PH, Jessica MM, Sriparna G, et al. Regulation of the hypothalamic-pituitary-adrenocortical stress response. Compr Physiol. 2016;6(2):603–621. doi: 10.1002/cphy.c150015
  13. Martin-Subero M, Anderson G, Kanchanatawan B, et al. Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. CNS Spectr. 2016;21(2):184–198. doi: 10.1017/S1092852915000449
  14. Martin CR, Osadchiy V, Kalani A, Mayer EA. The brain-gut-microbiome axis. Cell Mol Gastroenterol Hepatol. 2018;6(2):133–148. doi: 10.1016/j.jcmgh.2018.04.003
  15. Ilchmann-Diounou H, Menard S. Psychological stress, intestinal barrier dysfunctions, and autoimmune disorders: an overview. Front Immunol. 2020;11:133–148. doi: 10.3389/fimmu.2020.01823
  16. Psikhosomaticheskie rasstroistva v praktike terapevta. (authors) Vinokur V.A., Grinevich V.B., Il’yashevich I.G. et al. Saint Petersburg: SpecLit; 2008. P. 65–84. (In Russ.)
  17. Sinniger V, Pellissier S, Fauvelle F, et al. A 12-month pilot study outcomes of vagus nerve stimulation in Crohn’s disease. Neurogastroenterol Motil. 2018;32(10):e13911. doi: 10.1111/nmo.13911
  18. Ge L, Liu S, Li S, et al. Psychological stress in inflammatory bowel disease: Psychoneuroimmunological insights into bidirectional gut–brain communications. Front Immunol. 2022;13:1016578. doi: 10.3389/fimmu.2022.1016578
  19. Meroni E, Stakenborg N, Gomez-Pinilla PJ, et al. Vagus nerve stimulation promotes epithelial proliferation and controls colon monocyte infiltration during DSS-induced colitis. Front Med (Lausanne). 2021;8:694268. doi: 10.3389/fmed.2021.694268
  20. Chen LM, Bao CH, Wu Y, et al. Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease. J Neuroinflammation. 2021;18(1):135. doi: 10.1186/s12974-021-02175-2
  21. Geremia A, Biancheri P, Allan P, et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):3–10. doi: 10.1016/j.autrev.2013.06.004
  22. Byrne G, Rosenfeld G, Leung Y, et al. Prevalence of anxiety and depression in patients with inflammatory bowel disease. Can J Gastroenterol Hepatol. 2017;2017:6496727. doi: 10.1155/2017/6496727
  23. Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: Findings from two nationally representative Canadian surveys. Inflamm Bowel Dis. 2006;12(8):697–707. doi: 10.1097/00054725-200608000-00005
  24. Yongwen NgJ, Chauhan U, Armstrong D, et al. Comparison of the prevalence of anxiety and depression between uncomplicated and complex IBD patient groups. Gastroenterol Nurs. 2018;41(5):427–435. doi: 10.1097/SGA.0000000000000338
  25. Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis. 2018;22(3):752–762. doi: 10.1097/MIB.0000000000000620
  26. Stamboltsyan VSh. Otsenka urovnya ispytuemogo stressa i ehmotsional’noi ustoichivosti u bol’nykh s vospalitel’nymi zabolevaniyami kishechnika. Proceedings of the all-Russian scientific and practical conference with international participation “Mechnikov readings”; Saint Petersburg: 25–26 Apr 2018. Saint Petersburg; 2018. P. 98. (In Russ.)
  27. Lewis K, Marrie RA, Bernstein CN, et al. The Prevalence and risk factors of undiagnosed depression and anxiety disorders among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(10):1674–1680. doi: 10.1093/ibd/izz045
  28. Romasenko LV, Makhov VM, Isaykina MA. Disorders of the anxiety-depressive spectrum in inflammatory bowel diseases (psychosomatic correlations). S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):9–13. (In Russ.) doi: 10.17116/jnevro20191190419
  29. Yuan X, Chen B, Duan Z, et al. Depression and anxiety in patients with active ulcerative colitis: crosstalk of gut microbiota, metabolomics and proteomics. Gut Microbes. 2021;13(1):1987779. doi: 10.1080/19490976.2021.1987779
  30. Araki M, Shinzaki S, Yamada T, et al. Psychologic stress and disease activity in patients with inflammatory bowel disease: A multicenter cross-sectional study. PLoS One. 2020;5(15):e0233365. doi: 10.1371/journal.pone.0233365
  31. Paulides E, Boukema I, van der Woude CJ, de Boer NKH. The Effect of psychotherapy on quality of life in IBD patients: a systematic review. Inflamm Bowel Dis. 2021;27(5):711–724. doi: 10.1093/ibd/izaa144
  32. Iskandar HN, Cassell B, Kanuri N, et al. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol. 2014;48(5):423–429. doi: 10.1097/MCG.0000000000000049
  33. Guemei AA, El Din NM, Baraka AM, El Said Darwish I. Do desipramine [10,11-Dihydro-5-[3-(methylamino) propyl]-5H-dibenz[b, f]azepine monohydrochloride] and Fluoxetine [N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-propan-1-amine] ameliorate the extent of colonic damage induced by acetic acid in rats? J Pharmacol Exp Ther. 2008;327(3):846–850. doi: 10.1124/jpet.108.141259
  34. Kristensen MS, Kjærulff TM, Ersbøll AK, et al. The influence of antidepressants on the disease course among patients with Crohn’s disease and ulcerative colitis-A Danish Nationwide Register-Based Cohort Study. Inflamm Bowel Dis. 2019;25(5):886–893. doi: 10.1093/ibd/izy367

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 70763 от 21.08.2017 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies